IBRX — ImmunityBio, Inc.
Is IBRX overbought or oversold? Here is the current MarketMoodz read.
ImmunityBio, Inc. (IBRX) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Biotechnology) last closed at $10.28. The rating moved from Neutral to Overbought on October 1, 2026.
- Public ratingOverbought (as of October 3, 2026)
- Last close$10.28
- Last changeMoved from Neutral to Overbought on October 1, 2026
- SectorHealthcare
- IndustryBiotechnology
See all overbought Healthcare stocks →
AI analysis
ImmunityBio, Inc. faces a mixed environment: sector‑level interest in late‑stage biologics and high‑conviction insider/specialist buying provide potential support for select assets, but macro risk aversion, a cooling IPO window, and renewed emphasis on drug pricing create meaningful near‑term headwinds. Limited disclosure in the provided dataset increases uncertainty about cash runway and dilution risk, making clinical milestones and partnership or M&A activity the primary drivers of upside. Near term, expect share price sensitivity to market liquidity, trial readouts, and any capital markets activity. Over a multi‑quarter horizon, successful pivotal data or strategic transactions would materially improve the outlook, while financing needs, regulatory/payer setbacks, or clinical failures would increase downside.
Key factors
- Late‑stage biologics investor interest supports secondary liquidity and M&A optionality for select specialty biotech names
- Ongoing macro risk‑off tone and IPO window cooling are reducing risk appetite for healthcare/deal financing, pressuring valuations and access to equity capital
- Ongoing policy pressure on drug pricing and payer negotiation (Medicare/IRA) creates headwinds for pricing leverage and market access for higher‑priced therapies
- Lack of readily available EDGAR/financial comparables in the provided data raises uncertainty about near‑term cash runway and dilution risk
- Clinical and partnership catalysts remain the primary path to re‑rating; success in late‑stage or pivotal readouts would materially change the outlook
Risks
- Clinical trial failure or delayed readouts that remove the primary path to revenue or strategic interest
- Financing and dilution risk if markets remain risk averse and the company needs to raise capital at depressed prices
- Regulatory and payer risk from Medicare drug‑price negotiation or adverse coverage decisions that compress realized pricing
- Broad market volatility and rotation to safe havens that reduce trading liquidity and investor interest in speculative biotech
- Execution risk on partnerships, manufacturing scale‑up, or commercialization planning if a program is approved
Latest MarketMoodz coverage
- Cramer Backs CAVA in Mad Money Lightning Round2026-06-16
- ImmunityBio Gains FDA Acceptance for Expanded ANKTIVA Use2026-05-20
- FDA Flags Anktiva Claims as ImmunityBio Pushes Regulatory Fixes2026-04-06
- NCCN Expands Anktiva Guideline for Papillary NMIBC; ImmunityBio Stock Rises2026-03-17
- ImmunityBio Resubmits ANKTIVA for Expanded NMIBC Use2026-03-09
See today's live rating, score and targets
Members see the live hourly rating for IBRX — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.